Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jan 8;28(3):817-22. doi: 10.1016/j.vaccine.2009.10.050. Epub 2009 Oct 30.

MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.

Author information

  • 1McKing Consulting Corporation, 1600 Clifton Rd. NE MS E-52, Atlanta, GA 30333, USA. bcho@cdc.gov

Abstract

The study evaluates the benefits of meningococcal conjugate vaccine (MCV4) vaccination against the burden of vaccine-associated Guillain-Barré Syndrome (GBS) using simulation. An 11-year-old cohort was followed over an 8-year period in a simulation model Table 3 Figs. 1 and 2 to estimate health outcomes to assist decision makers in setting policy. Applying a 3% discount rate, MCV4 vaccination would save 2397 quality-adjusted life years (QALYs) while vaccine-attributable GBS could result in 5 QALYs lost. Based on the result, MCV4 vaccination is strongly favored despite possible vaccine-associated GBS risk.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk